Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (20040)	5/6/1998 6:39:00 AM
From: Henry Niman	Read Replies (2) of 32384

Speaking of a "war on cancer", today's WSJ article describes progress on approaches targeting oncogenes. Although LGND isn't mentioned (they don't specifically target oncogenes), oncogenes played a major role in the formation of Ligand. The formation of Progenx was based on monoclonal antibodies that were directed against monoclonal antibodies directed against synthetic peptides that represented proteins encoded by oncogenes. One of the oncogenes was erb-A which was a mutated and shortened version of the thyroid hormone receptor. I had been collaborating with Ron Evans and when CEO Howard Birndorf went to talk to him about joining Progenx's scientific advisory board, it became clear that Ron was interested in comercially developing his IR technology. Progenx exclusively licensed the technology from Salk and then switch from a cancer diagnositic company to a cancer therapeutics company and changed its name to Ligand.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next